10.05.15
Evotec AG has entered into a multi-year agreement with the U.S. National Cancer Institute (NCI), Department of Health and Human Services to provide compound management services to the NCI Chemical Biology Consortium (CBC) for five years.
The NCI Chemical Biology Consortium contract, valued at $4.9 million, will continue to acquire, store, maintain and distribute the current library collection. This repository will form part of the CBC's drug discovery and development platform for new oncology therapeutics being researched by a consortium of academic and non-profit institutions.
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are pleased the NCI has elected to award Evotec this important contract to support the Chemical Biology Consortium, an important initiative in the discovery of new cancer treatments."
The NCI Chemical Biology Consortium contract, valued at $4.9 million, will continue to acquire, store, maintain and distribute the current library collection. This repository will form part of the CBC's drug discovery and development platform for new oncology therapeutics being researched by a consortium of academic and non-profit institutions.
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are pleased the NCI has elected to award Evotec this important contract to support the Chemical Biology Consortium, an important initiative in the discovery of new cancer treatments."